GlycoGenesys, Inc., (Nasdaq: GLGS), a biotechnology company developing carbohydrate-based drugs, announced earlier today that it was awarded a favorable ruling in the arbitration proceedings brought by the Company against David Platt, its former CEO. With this favorable decision in hand, GlycoGenesys is taking the opportunity to describe the separate litigation with Platt and Pro-Pharmaceuticals, Inc. (AMEX:PRW), the company Platt now heads, and its business implications. This separate litigation, regardless of outcome, does not affect our rights to pursue commercialization of GCS-100.
